| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 肠胃用药(元) | 103,388,590.49 | 206,272,180.38 | 93,107,694.11 |
| 两性健康用药(元) | 66,743,966.84 | 177,837,304.59 | 130,224,187.00 |
| 眼科用药(元) | 79,383,497.50 | 184,580,782.89 | 87,258,565.29 |
| 中成药及外用药(元) | 66,800,997.56 | 94,771,876.46 | 54,122,372.40 |
| 医疗器械(元) | - | 30,125,199.03 | - |
| 医药技术服务及技术转让(元) | - | 10,866,218.20 | - |
| 原料药(元) | - | 10,034,297.63 | - |
| 其他主营产品(元) | - | 5,680,611.43 | - |
| 营业成本(元) | |||
| 肠胃用药(元) | 19,833,639.16 | 40,012,085.98 | 17,618,203.50 |
| 两性健康用药(元) | 10,107,919.88 | 23,149,151.68 | 11,239,943.29 |
| 眼科用药(元) | 47,562,666.52 | 110,309,223.92 | 52,140,719.16 |
| 中成药及外用药(元) | 60,282,963.77 | 92,692,868.67 | 50,425,576.42 |
| 医疗器械(元) | - | - | - |
| 医药技术服务及技术转让(元) | - | - | - |
| 原料药(元) | - | - | - |
| 其他主营产品(元) | - | - | - |
| 毛利(元) | |||
| 肠胃用药(元) | 83,554,951.33 | 166,260,094.40 | 75,489,490.61 |
| 两性健康用药(元) | 56,636,046.96 | 154,688,152.91 | 118,984,243.71 |
| 眼科用药(元) | 31,820,830.98 | 74,271,558.97 | 35,117,846.13 |
| 中成药及外用药(元) | 6,518,033.79 | 2,079,007.79 | 3,696,795.98 |
| 医疗器械(元) | - | - | - |
| 医药技术服务及技术转让(元) | - | - | - |
| 原料药(元) | - | - | - |
| 其他主营产品(元) | - | - | - |
| 毛利率(%) | |||
| 肠胃用药(%) | 80.82 | 80.60 | 81.08 |
| 两性健康用药(%) | 84.86 | 86.98 | 91.37 |
| 眼科用药(%) | 40.08 | 40.24 | 40.25 |
| 中成药及外用药(%) | 9.76 | 2.19 | 6.83 |
| 医疗器械(%) | - | - | - |
| 医药技术服务及技术转让(%) | - | - | - |
| 原料药(%) | - | - | - |
| 其他主营产品(%) | - | - | - |
| 收入构成(%) | |||
| 肠胃用药(%) | 32.69 | 28.64 | 25.53 |
| 两性健康用药(%) | 21.10 | 24.69 | 35.71 |
| 眼科用药(%) | 25.10 | 25.63 | 23.93 |
| 中成药及外用药(%) | 21.12 | 13.16 | 14.84 |
| 医疗器械(%) | - | 4.18 | - |
| 医药技术服务及技术转让(%) | - | 1.51 | - |
| 原料药(%) | - | 1.39 | - |
| 其他主营产品(%) | - | 0.79 | - |
| 毛利构成(%) | |||
| 肠胃用药(%) | 46.80 | 41.85 | 32.36 |
| 两性健康用药(%) | 31.72 | 38.93 | 51.00 |
| 眼科用药(%) | 17.82 | 18.69 | 15.05 |
| 中成药及外用药(%) | 3.65 | 0.52 | 1.58 |
| 医疗器械(%) | - | 0.00 | - |
| 医药技术服务及技术转让(%) | - | 0.00 | - |
| 原料药(%) | - | 0.00 | - |
| 其他主营产品(%) | - | 0.00 | - |